

(19)



(11)

EP 3 954 764 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)**Corrections, see****Bibliography INID code(s) 73**

(48) Corrigendum issued on:

30.04.2025 Bulletin 2025/18

(45) Date of publication and mention of the grant of the patent:

19.02.2025 Bulletin 2025/08(21) Application number: **19924173.8**(22) Date of filing: **04.11.2019**

(51) International Patent Classification (IPC):

C12N 5/09 (2010.01) C12Q 1/02 (2006.01)

(52) Cooperative Patent Classification (CPC):

C12N 5/0693; C12N 5/0679; C12N 2500/25; C12N 2500/32; C12N 2501/11; C12N 2501/119; C12N 2501/12; C12N 2501/415; C12N 2501/727; C12N 2501/734

(86) International application number:

PCT/CN2019/115306

(87) International publication number:

WO 2020/206999 (15.10.2020 Gazette 2020/42)(54) **METHOD FOR CULTURING PRIMARY CELLS OF GASTRIC CANCER AND GALLBLADDER AND BILE DUCT CANCER, AND SUPPORTING REAGENTS**

VERFAHREN ZUR ZÜCHTUNG VON PRIMÄRZELLEN VON MAGENKREBS UND GALLENBLASEN- UND GALLENGANGSKREBS UND UNTERSTÜTZENDE REAGENZIEN

PROCÉDÉ DE CULTURE DE CELLULES PRIMAIRES DE CANCER GASTRIQUE ET DE CANCER DE LA VÉSICULE BILIAIRE ET DE CANAL CHOLÉDOQUE, ET RÉACTIFS DE SUPPORT

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR(30) Priority: **11.04.2019 CN 201910289073****11.04.2019 CN 201910289074**

(43) Date of publication of application:

16.02.2022 Bulletin 2022/07(73) Proprietor: **GeneX Health Co., Ltd****Beijing 100195 (CN)**

(72) Inventors:

- **YIN, Shenyi**
Beijing 101105 (CN)
- **ZHANG, Hanshuo**
Beijing 101105 (CN)

(74) Representative: **Isarpatent****Patent- und Rechtsanwälte Barth
Charles Hassa Peckmann & Partner mbB
Friedrichstrasse 31
80801 München (DE)**

(56) References cited:

WO-A1-2018/096881 CN-A- 103 194 429
CN-A- 103 966 168 CN-A- 104 403 996
CN-A- 104 560 878 CN-A- 105 229 150
CN-A- 108 624 561 US-A1- 2012 164 732
US-A1- 2014 243 227

- **GEORGIOS VLACHOGIANNIS ET AL: "Patient-derived organoids model treatment response of metastatic gastrointestinal cancers", SCIENCE, vol. 359, no. 6378, 23 February 2018 (2018-02-23), US, pages 920 - 926, XP055596283, ISSN: 0036-8075, DOI: 10.1126/science.aao2774**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).